HSA
PACB icon

Hussman Strategic Advisors’s Pacific Biosciences PACB Stock Holding History

Hussman Strategic Advisors’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-52,500
Closed -$438K – 283
2023
Q3 		$438K Buy
+52,500
New +$600K 0.08% 246

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
MA
Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Hussman Strategic Advisors's PACB Position: Q4 2023 in Review

Hussman Strategic Advisors sold out of Pacific Biosciences (PACB) in Q4 2023, closing a stake of 52,500 shares — an estimated $438K sold.

Hussman Strategic Advisors first reported a position in PACB in Q3 2023 and held it in 1 quarter. The position peaked at $438K in Q3 2023. 274 funds tracked by Wall St. Rank hold PACB as of Q4 2023.

  • Hussman Strategic Advisors reported no remaining Pacific Biosciences position as of Q4 2023 after selling out during the quarter.
  • Hussman Strategic Advisors sold 52,500 Pacific Biosciences shares in Q4 2023, an estimated $438K.
  • Hussman Strategic Advisors first reported a position in Pacific Biosciences in Q3 2023 and held it in 1 quarter.
  • Hussman Strategic Advisors's Pacific Biosciences position peaked at $438K in Q3 2023.
  • 274 funds tracked by Wall St. Rank held Pacific Biosciences as of Q4 2023.

Based on Hussman Strategic Advisors's 13F filing for Q4 2023, filed 1 Feb 2024.